Tactile Systems presents new clinical data at ASCO on Flexitouch

Tactile Systems (TCMD) Technology announced the presentation of new clinical data at the American Society of Clinical Oncology, ASCO, 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company’s Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. Two-month data demonstrated that usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed: Usual care participants took an average of 29.8 days to begin therapist guided lymphedema treatment, while APCD participants received their device in 17.9 days; Of participants randomized to usual care, only 71% received TGLT compared to 94.9% of those in the APCD group; APCD participants had significant reduction in swelling via digital photography and total Head and Neck Cancer Related Lymphedema and Fibrosis Grading scores while usual care participants exhibited marginal improvements; and Self-reported symptom improvement occurred in both groups, with APCD demonstrating significant improvement on three of the six health-related quality-of-life sub scales.